June 5, 2020
In physics, the terms snap, crackle and pop are sometimes used to describe the fourth, fifth- and sixth-time derivatives of position. The first derivative of position with respect to time is velocity, the second is acceleration, and the third is jerk (or jolt also with respect to time).
Pre-open indications: 3 BUYs and 2 SELLs
What I provide is an “intelligence daily” to “never leave an investor uninformed”! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors who make money and for those who read and don’t weep!
Can you afford NOT to read it?
June 3, 2020
NTLA priced an offering of 5,479,453 shares of its common stock at a public offering price of $18.25 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 821,917 shares
The gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses have increased to $100 million from $75 million
NTLA closed down -$0.66 to $20.26
June 5, 2020
A stunning blowout and reversal in non-farm payroll numbers – they decreased however; sector under-performance continues with sentiment spoilage
Pre-open indications follow-up results: 4 HITs and 1 MISS <who>
Week in review …
An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector. Who is feeding your portfolio – profit from RMi’s analysis! Check the BOTTOM LINE <never leave an investor uninformed >
Subscription is coming, it’s not a conscription but, an offer to join our collective of like-minded investors who make money and for those who read and don’t weep!
June 3, 2020
NTLA priced an offering of 5,479,453 shares of its common stock at a public offering price of $18.25 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 821,917 shares The gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses have increased to $100 million from $75 million NTLA closed down -$0.66 to $20.26
May 30, 2020
A scorecard of 32 (added PSTI) earnings "confessions", 1 restatement and 1 acquisition of 35 covered companies Added Mesoblast (MESO) and Precision (PGEN) The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
May 26, 2020
Regenerative Medicine Earnings listing for Q1/20 My focus is to define the net income or loss, the per share amounts commonly an LPS (loss-per-share), cash positions (EOQ – “end-of-quarter”) and the “runway” of continuing operations.
June 5, 2020
RegMed Investors’ (RMi) closing bell: sold-out by strength
June 5, 2020
RegMed Investors’ (RMi) pre-open: after a market snap, a crackle, pop and a better than feared jobs report
June 4, 2020
RegMed Investors’ (RMi) closing bell: sector set-back
June 4, 2020
RegMed Investors’ (RMi) pre-open: you know what they say about highs, they only last so long
June 3, 2020
RegMed Investors’ (RMi) closing bell: cause and effect
June 3, 2020
Intellia Therapeutics (NTLA) prices $100 million offering at $18.25
June 3, 2020
RegMed Investors’ (RMi) pre-open: tear gas drifts over optimism on the curfewed and reopening streets
June 2, 2020
RegMed Investors’ (RMi) closing bell: are “things” good or less bad
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
